share_log

Needham Maintains Buy on Heron Therapeutics, Lowers Price Target to $4

Benzinga ·  Nov 15, 2023 07:49

Needham analyst Serge Belanger maintains Heron Therapeutics (NASDAQ:HRTX) with a Buy and lowers the price target from $5 to $4.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment